---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Generic, brand name and therapeutic class of product"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Generic, brand name and therapeutic class of product. Topics: Manufacturer: Olema Oncology, Development code and nonproprietary name, Therapeutic class: complete estrogen receptor antagonist and selective estrogen receptor degrader, International nonproprietary name: proposed in 2022, and 1 further topic. 5 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/generic-brand-name-and-therapeutic-class-of-product"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Generic, brand name and therapeutic class of product

<a id="heading-2.1.2.1"></a>

## 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

### Manufacturer: Olema Oncology

> “Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.)”
> “Nov. 12, 2026”

Source: [Olema Oncology corporate name change announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-corporate-name-change)

<a id="topic-2.1.2.1-2"></a>

### Development code and nonproprietary name

> “Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials.”

Source: [Olema Oncology third quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2026-financial-and)

<a id="topic-2.1.2.1-3"></a>

### Brand name

No evidence found.

<a id="topic-2.1.2.1-4"></a>

### Therapeutic class: complete estrogen receptor antagonist and selective estrogen receptor degrader

> “Here, we describe our discovery of the investigational drug OP-1250 (palazestrant). OP-1250 is a potent complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) that is active in both WT and mutESR1 breast cancer tumors.”

Source: [Ng et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163657/)

> “Palazestrant (OP-1250) is a novel, orally available small molecule with dual activity as both a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD).”

Source: [Olema Oncology third quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2026-financial-and)

<a id="topic-2.1.2.1-5"></a>

### International nonproprietary name: proposed in 2022

> “Proposed INN: List 128”
> “palazestrantum”
> “antiestrogen, antineoplastic”
> “C28H36FN3O”
> “2092925-89-6”

Source: [WHO Proposed INN List 128 (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl128.pdf)

<a id="topic-2.1.2.1-6"></a>

### International nonproprietary name: recommended in 2023

> “WHO Drug Information, Vol. 37, No. 3, 2023”
> “Recommended INN: List 90”
> “palazestrantum”

Source: [WHO Recommended INN List 90 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl90.pdf)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
